10.22376/ijpbs.2019.10.1.p1-12 Volume 4 Issue 3 2013 (July - September) Human papillomaviruses are the primary etiologic agents of cervical cancer. Thus, cervical cancer and other Human papillomavirus associated malignancies might be prevented by Human papillomavirus vaccines. Currently, two Human papillomavirus L1 Virus -Like Particle vaccines namely Gardasil lessThan sup greaterThan ® lessThan /sup greaterThan - quadrivalent (Merck) and Cervarix™ - bivalent (GlaxoSmithKline) are widely marketed internationally. These HPV vaccines are commercially available. The advisable period of Human papillomavirus vaccination is before the onset of sexual activity. Human papillomavirus vaccines should not be given to people who have experienced severe allergic reactions after a previous vaccine dose or to a component of the vaccine. These vaccines are not recommended for use in pregnant females. The mechanisms by which these vaccines induce protections are not fully defined but involve both cellular immunity and neutralizing immunoglobulin G antibodies. This review brings up to date information on the two commercially available prophylactic Human papillomavirus vaccines. VIKRANT C. SANGAR AND DR. B. B. GHONGANE Prophylactic Human papillomavirus vaccines, Virus-like particles vaccine preparation, Competitive radioimmunoassay, Pseudovirion-based neutralization assay, Human papillomavirus vaccines clinical trials in INDIA. 124-133